A. Luke Smith

A. Luke Smith

Attorney A. Luke Smith joined Radice Law Firm PC as an associate in 2014. Mr. Smith has considerable experience litigating all phases of complex antitrust class actions, from pre-filing investigations through post-trial briefing. Throughout his career, Mr. Smith has had the privilege of working alongside the nation’s most preeminent plaintiffs law firms and lawyers, and has been part of the litigation or trial teams in, inter alia, the following cases:

  • In re Metoprolol Succinate Direct Purchaser Antitrust Litigation, 06-52 (D. Del.) ($20 million settlement in case challenging Astra-Zeneca conduct to delay generic entry)
  • In re Wellbutrin XL Antitrust Litigation, No. 08-2431 (E.D. Pa.) ($37.5 million partial settlement in case challenging the conduct of SmithKline Beecham Corp. and Biovail Laboratories in delaying generic drug competition)
  • In re Prandin Direct Purchaser Antitrust Litigation, 10-12141AC-DAS (E.D. Mich.) ($19 million settlement in case challenging Novo Nordisk’s conduct to delay generic entry)
  • Marchese v. Cablevision Systems Corporation, 2:10-cv-02190 (D.N.J.) (accusing Cablevision of illegally tying two-way cable services to rentals of a Cablevision-supplied set-top box)
  • In re Skelaxin (metaxalone) Direct Purchaser Antitrust Litigation, 12-2343 (E.D. Tenn.) ($73 million settlement in case alleging delayed generic entry)
  • In re Nexium (Esomeprazole) Antitrust Litigation, 1:12-md-02409 (D. Mass.) ($24 million partial mid-trial settlement in “pay-for-delay” case challenging agreements between AstraZeneca and generic competitors to delay generic entry)
  • Smith v. FDA, 12-5141 (pro se case challenging FDA’s public disclosure policies under FOIA)
  • In re Solodyn Antitrust Litig., No. 14-10438 (D. Mass.) (alleging that Medicis engaged in an anticompetitive scheme to delay generic competition)
  • In re Lidoderm Antitrust Litig., No. 14-2521 (N.D. Cal.) (alleging that Endo paid its generic competitor, Watson (now known as Actavis), to delay generic versions of Lidoderm.

Mr. Smith recently co-authored an article on abusive “life cycle management” practices in the pharmaceutical industry, “Life Cycle Management: The Courts Examine Brand Strategies to Defend Blockbuster Franchises” (ABA Antitrust Law Division, 63rd Spring Meeting, April 15-17, 2015).

Mr. Smith earned his J.D. from Pennsylvania State University Dickinson School of Law (2010), and graduated summa cum laude from Cheyney University of Pennsylvania with a degree in Business Management (2007). While in law school, Mr. Smith was certified as a Miller Center Public Interest Advocate in recognition of his service at the Family Law Clinic, and competed in the American Constitution Society Constance Baker Motley National Moot Court Competition. Mr. Smith has completed internships for the Honorable Joseph A. Greenaway, then of the United States District Court for the District of New Jersey, the New Jersey Office of the Public Defender, and at the Pennsylvania Attorney General, Bureau of Consumer Protection.

Mr. Smith also devotes significant energy serving his community, and in 2012 co-founded Germantown United CDC (a 501(c)(3) revitalizing Germantown’s business corridors through a community-driven approach to economic development), where he currently serves as secretary of the board and a member of the executive committee. He is also a board member of the Ebenezer Maxwell Mansion (an authentically restored Victorian house museum in Philadelphia), and is V.P. and Chair of the Zoning Committee for WCGN (neighborhood civic association and RCO representing Tulpehocken Historic Station District). Mr. Smith also serves as Democratic Committee Person for Philadelphia’s 59th Ward, 22 Division, after his public election to that post in 2014.

Mr. Smith is licensed to practice in Pennsylvania and New Jersey has been admitted to the United States District Courts for the Eastern District of Pennsylvania and the District of New Jersey.